While these technologies are now a therapeutic reality, the ASGCT 2024 annual meeting this week was a reminder of just how ...

Anticipating approval for its COPD therapy ensifentrine, Verona has entered into a $650 million financing deal with Oaktree ...

With its $525 million investment, Royalty Pharma will acquire the royalties and milestones for ImmuNext’s anti-CD40 therapy ...

Novavax Soars on $1.4B Deal With Sanofi for COVID Vaccine - read this article along with other careers information, tips and ...

ASGCT 2024 session, CBER Director Peter Marks made the case for a better, “more convergent” global framework on cell and gene ...

Takeda saw a 57% drop in profit in its 2023 fiscal year and has lowered its outlook for the coming fiscal year, mostly driven ...

An autologous and personalized regulatory T cell therapy is safe in patients with type 1 diabetes, but does not help preserve ...

The Bay Area–based biotech plans to use the funds to advance two lead programs, one to treat atopic dermatitis and another ...

Jeffrey Chamberlain, president of the American Society of Gene & Cell Therapy, spoke with BioSpace about what we can expect ...

Cell and gene therapy company Cellectis announced Monday it has completed a $140 million investment from AstraZeneca that ...

With three FDA approvals in the past 10 months, there is a lot of momentum in the Duchenne muscular dystrophy space. Here are ...

Following the regulatory victory of Balversa in urothelial carcinoma, Johnson & Johnson on Friday continued its bladder ...